#75
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians treating older adults should understand that this population may have specific cannabinoid preferences, with many favoring CBD-dominant or balanced CBD/THC products over THC-heavy formulations, which can inform individualized treatment recommendations. This preference data is particularly relevant for geriatric patients concerned about psychoactive effects or cognitive impacts, allowing providers to align cannabis-based therapies with patient expectations and safety profiles. Knowledge of these patient preferences enables clinicians to have more informed discussions about cannabinoid ratios when considering cannabis as an option for pain, anxiety, or other conditions in older populations.
Recent research published in JAMA Network Open indicates that older adults selecting medicinal cannabis demonstrate a preference for cannabidiol (CBD)-dominant or balanced CBD/THC combination products rather than THC-dominant formulations. This preference pattern reflects both safety considerations and efficacy expectations in an aging population, as older adults may be more vulnerable to THC-related adverse effects such as cognitive impairment, orthostatic hypotension, and drug interactions with concurrent medications. Understanding these age-specific product preferences is clinically relevant since clinicians increasingly encounter older patients seeking cannabis for conditions like chronic pain, anxiety, and sleep disturbance, where evidence increasingly supports CBD efficacy with lower toxicity profiles. The findings suggest that when prescribing or recommending medicinal cannabis to older adult patients, starting with CBD monotherapy or lower-THC formulations may align with patient preferences while potentially reducing risks associated with higher THC exposure. Clinicians should engage in shared decision-making conversations about cannabinoid ratios and educate older patients that product selection significantly influences both therapeutic outcomes and safety profiles.
“What we’re seeing in older patients is a clear preference for either pure CBD or balanced ratios, and that’s clinically sound because they’re often managing multiple medications and have lower tolerance for intoxicating effects, yet they still want therapeutic benefit for pain, anxiety, or sleep. The data validates what I’ve observed in my practice: when we respect patients’ desire to avoid impairment while still accessing cannabinoid medicine, adherence improves and side effects decrease.”
? This emerging preference data among older adults for CBD-predominant or balanced CBD/THC products reflects both pharmacological rationale and individual risk tolerance, yet clinicians should recognize that product preferences do not necessarily equate to efficacy or safety in this vulnerable population. Older adults face particular concerns around THC’s psychoactive effects, cognitive impacts, and drug interactions, which reasonably motivates interest in lower-THC options, though rigorous clinical evidence supporting CBD monotherapy for most conditions remains limited. The heterogeneity of cannabis products, inconsistent labeling, and lack of standardization across jurisdictions further complicate translation of user preference studies into clinical guidance. Clinicians caring for older patients considering medicinal cannabis should engage in shared decision-making that acknowledges these preference patterns while emphasizing the need for careful baseline assessment, drug-drug interaction screening, and individualized dosing given the pharmacokinetic changes of aging and sparse safety data in
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
